442549-68-0 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 8-bromo-6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate is used as a key intermediate in the synthesis of antibacterial and antifungal agents. Its broad-spectrum activity against a variety of pathogens makes it a promising candidate for the development of new drugs with improved efficacy and safety profiles.
Used in Agrochemicals:
Methyl 8-bromo-6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate has potential applications in the field of agrochemicals, where it can be utilized for the development of novel pesticides and fungicides to protect crops from various pathogens.
Used in Veterinary Medicine:
In the veterinary medicine industry, Methyl 8-bromo-6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate can be employed for the synthesis of drugs to treat bacterial and fungal infections in animals, ensuring their health and well-being.
Check Digit Verification of cas no
The CAS Registry Mumber 442549-68-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,2,5,4 and 9 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 442549-68:
(8*4)+(7*4)+(6*2)+(5*5)+(4*4)+(3*9)+(2*6)+(1*8)=160
160 % 10 = 0
So 442549-68-0 is a valid CAS Registry Number.
442549-68-0Relevant articles and documents
Synthesis of novel quinolone and quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)amides: A late-stage diversification approach to potent 5HT1B antagonists
Horchler, Carey L.,McCauley Jr., John P.,Hall, James E.,Snyder, Dean H.,Craig Moore,Hudzik, Thomas J.,Chapdelaine, Marc J.
, p. 939 - 950 (2007/10/03)
Multiparallel amenable syntheses of 6-methoxy-8-amino-4-oxo-1,4-dihydroquinoline-2-carboxylic acid-(4-morpholin-4-yl-phenyl)amides (I) and 4-amino-6-methoxy-8-(4-methyl-piperazin-1-yl)-quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)amides (II) which facilitate late-stage diversification at the 8-position of (I) and at the 4- and 8-positions of (II) are described. The resulting novel series were determined to contain potent 5HT1B antagonists. Preliminary SAR data are presented.
